Saudi Arabia Pharmaceutical Logistics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The saudi arabia pharmaceutical logistics market size was valued at USD 3.28 billion in 2025 and estimated to grow from USD 3.48 billion in 2026 to reach USD 4.62 billion by 2031, at a CAGR of 5.84% during the forecast period (2026-2031). This report is Segmented by Logistics Function (Transportation, Warehousing & Distribution, Value-Added Services), by Mode of Operation (Cold-Chain, Non-Cold-Chain), by Product Type (Prescription Drugs, OTC Drugs, Biologics, Clinical Trial Materials, Cell & Gene Therapies, and More), and by Region(Central, Eastern, Western, Northern, Southern). The Forecasts are Provided in Terms of Value (USD).

Saudi Arabia Pharmaceutical Logistics Market Trends and Insights

Vision 2030 Healthcare Transformation

Saudi Arabia’s healthcare overhaul is changing the demand profile of the Saudi Arabia pharmaceutical logistics market beyond the effect of new hospitals alone. The 2025 national budget allocated SAR 260 billion (USD 69 billion) to health and social development, which kept healthcare among the Kingdom’s largest spending priorities. The plan to corporatize and privatize 290 hospitals and 2,300 primary health centers increases the number of operating nodes that need regular medicine replenishment and service-level consistency. This shift reduces reliance on a single centralized distribution logic and raises the value of providers that can manage more institutional buyers, denser routes, and tighter inventory visibility. In practice, the Saudi Arabian pharmaceutical logistics market benefits from healthcare reform, which makes delivery reliability a core operating requirement rather than a support function.

SFDA Cold-Chain Regulation Enforcement

The Saudi Arabia pharmaceutical logistics market is being lifted by tighter SFDA enforcement of Good Distribution Practice standards across temperature-sensitive handling. Continuous data logging, automated temperature deviation alerts, and validated sensor coverage are now embedded in compliance expectations for cold-chain shipments, which raises the infrastructure threshold for service providers. Operators without certified equipment and documented processes are increasingly excluded from high-value biologic and vaccine tenders, which shifts more volume toward qualified networks. The SFDA’s audit and licensing activities are also driving new investment in warehouse validation, fleet upgrades, and reporting systems across the Kingdom. A parallel constraint remains on the labor side, as the 2025 logistics skills report identified major gaps in digital tools, cold-chain management, and specialized logistics roles, with 42% of logistics companies reporting that many employees still lacked these capabilities.

High Cold-Chain Operating Costs In Desert Climate

The Saudi Arabia pharmaceutical logistics market faces a persistent cost burden because GDP-compliant refrigeration in desert conditions requires heavier cooling loads than most temperate-climate systems. Summer temperatures above 45 °C raise energy use, shorten equipment life, and increase maintenance cycles across warehouses, trucks, and airport handling facilities. Smaller operators feel this pressure most because they do not have the asset scale or route density that global 3PLs can use to spread fixed costs across larger throughput. The challenge becomes sharper in cryogenic logistics, where storage at very low temperatures creates a separate cost structure above standard 2-8 °C operations. Energy optimization pilots using AI and ML have shown potential in Riyadh and Jeddah, but adoption remains limited because the upfront capital requirements remain high.

Other drivers and restraints analyzed in the detailed report include:

• Rising Chronic-Disease Demand For Biologics
• Growth Of E-Pharmacy And Home Delivery
• Customs Clearance Delays

Segment Analysis

Transportation accounted for 62.78% of the Saudi Arabia pharmaceutical logistics market share in 2025, confirming that cross-border movement and domestic line-haul still form the commercial core of the sector. This dominance reflects the import-driven structure of Saudi medicine supply, where large inbound volumes enter through key airports and seaports before moving into hospital, pharmacy, and government procurement channels. Road transport remains the main distribution backbone from ports and airports into secondary cities and care networks, offering the broadest reach across the Kingdom. Air freight continues to play a critical role in the movement of urgent biologics and specialty products through Riyadh and Jeddah. At the same time, sea routes through Jeddah and Dammam continue to handle bulk pharmaceutical volumes at lower unit cost.

Value-added services are projected to grow at 8.76% CAGR through 2031, making them the fastest-moving part of the functional mix in the Saudi Arabia pharmaceutical logistics market. This growth comes from rising demand for serialization support, GDP documentation, temperature excursion reporting, reverse logistics, and direct-to-patient fulfillment rather than from transport volume alone. Warehousing and distribution are also being repositioned from a cost center into a resilience asset as the government hub strategy encourages larger in-country buffer stocks at Riyadh, Jeddah, and other strategic nodes. DHL Supply Chain’s EUR 130 million (USD 141 million) investment in a 78,000 m² multi-user warehouse at Riyadh’s SILZ illustrates this shift. It shows how capacity expansion is being tied directly to pharmaceutical service depth rather than simple storage growth.

Complete Report Scope:

• By Logistics Function
  • Transportation
    • Road
    • Air
    • Sea and Inland Waterways
    • Rail
  • Warehousing and Distribution
  • Value-added Services and Others
• By Mode of Operation
  • Cold-Chain Logistics
  • Non-Cold-Chain Logistics
• By Product Type
  • Prescription Drugs
  • OTC Drugs
  • Biologics and Biosimilars
  • Vaccines and Blood Products
  • Clinical Trail Materials
  • Cell and Gene Therapies
  • Medical Devices and Diagnostics
  • Veterinary Medicine
  • Others
• By Region
  • Central (Riyadh, Al-Qassim, and Hail)
  • Eastern (Ash-Sharqiyah)
  • Western (Al-Bahah, Makkah, Medina, and Tabuk)
  • Northern (Al-Jouf and Arar)
  • Southern (Asir, Jazan, and Najran)

List of Companies Covered in this Report:

• DHL Group
• Tamer Logistics
• Kuehne+Nagel
• UPS
• DSV (Incl. DB Schenker)
• Flow Progressive Logistics
• ADQ
• SAL Saudi Logistics Services
• CEVA Logistics (CMA CGM Group)
• Almajdouie Logistics
• FedEx
• NAQEL Express
• Hellmann Worldwide Logistics
• Expeditors International
• Bahri Logistics
• GAC Saudi Arabia
• Proceed Logistics
• Medical Support 1
• Yusen Logistics
• Mosanada Logistics Services
• Wared Logistics

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support